Cognition Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
Cognition Therapeutics CEO'su Lisa Ricciardi, Mar2020 tarihinde atandı, in görev süresi 6.5 yıldır. in toplam yıllık tazminatı $ 1.46M olup, şirket hissesi ve opsiyonları dahil olmak üzere 44.6% maaş ve 55.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.52% ine doğrudan sahiptir ve bu hisseler $ 487.80K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 6.8 yıldır.
Anahtar bilgiler
Lisa Ricciardi
İcra Kurulu Başkanı
US$1.5m
Toplam tazminat
| CEO maaş yüzdesi | 44.60% |
| CEO görev süresi | 6.5yrs |
| CEO sahipliği | 0.5% |
| Yönetim ortalama görev süresi | 3.5yrs |
| Yönetim Kurulu ortalama görev süresi | 6.8yrs |
Son yönetim güncellemeleri
Recent updates
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential
Catalysts About Cognition Therapeutics Cognition Therapeutics is a clinical stage biopharmaceutical company focused on developing zervimesine for neurodegenerative diseases such as dementia with Lewy bodies and Alzheimer's disease. What are the underlying business or industry changes driving this perspective?We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, Cognition...We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease
Summary Cognition Therapeutics' stock dropped over 40% after Phase 2 trial results for Alzheimer's disease. Results showed cognitive benefit but fading statistical significance over time. CT1812 did not outperform placebo on all rating scales over 3-6 months, raising concerns for future milestones and larger trials. Financial reliance on NIH grants poses risks, and ongoing trials in dementia with Lewy Bodies, Alzheimer's and dry AMD have the potential for further stock decline. Read the full article on Seeking AlphaIs Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Summary Cognition Therapeutics is set to report topline data from its Phase 2 trial in Alzheimer's disease in mid-2024. CT1812, the company's lead drug candidate, is a sigma-2 receptor antagonist for Alzheimer's and aims to prevent the binding of toxic Aβ oligomers. Preliminary data from the ongoing SHINE trial showed some interesting results, but were not consistent with other previous studies, raising caution about the upcoming data. At a ~$70 million market cap with about half of that cash, the topline readout could be a binary event for the stock. Read the full article on Seeking AlphaHere's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Cognition Therapeutics (NASDAQ:CGTX) said it received a $2.14M grant from the National Institute on Aging (NIA) to help complete an ongoing study of CT1812 in adults with mild-to-moderate Alzheimer's disease. The study called SEQUEL will evaluate if CT1812 results in a normalization of the EEG patterns. The trial is enrolling 16 adults who will receive either CT1812 or placebo, the company said in a Sept. 27 press release. Cognition noted that the study is taking place at the Amsterdam UMC Dept. of Neurology/Alzheimer Center and Brain Research Center. The NIA, a division of the National Institutes of Health (NIH), awarded a $3.2M grant in 2020 to support the study and has now awarded $2.14M, the company added. CGTX +12.28% to $1.92 premarket Sept. 27We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
An analysis of biomarker data from Cognition Therapeutics' (NASDAQ:CGTX) Alzheimer's disease candidate CT1812 indicate the oral once-daily treatment supports a synaptoprotective mechanism of action and has a role in normalizing cellular processes. Proteomic analyses demonstrated CT1812's impact on several Alzheimer's biomarkers, including YKL-40, which is an indicator of inflammation and is upregulated in the disease. Results showed that participants given CT-1812 saw declining levels of YKL-40. The candidate also had a significant impact on cerebrospinal fluid levels of clusterin, a genetic risk factor for Alzheimer's. Cognition closed up 62% on Thursday but is down 16% in Friday premarket trading.CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$17m |
| Mar 31 2026 | n/a | n/a | -US$20m |
| Dec 31 2025 | US$1m | US$651k | -US$23m |
| Sep 30 2025 | n/a | n/a | -US$28m |
| Jun 30 2025 | n/a | n/a | -US$33m |
| Mar 31 2025 | n/a | n/a | -US$33m |
| Dec 31 2024 | US$2m | US$629k | -US$34m |
| Sep 30 2024 | n/a | n/a | -US$34m |
| Jun 30 2024 | n/a | n/a | -US$31m |
| Mar 31 2024 | n/a | n/a | -US$29m |
| Dec 31 2023 | US$2m | US$587k | -US$26m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$24m |
| Dec 31 2022 | US$1m | US$550k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$22m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$11m | US$409k | -US$16m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$10m |
| Mar 31 2021 | n/a | n/a | -US$9m |
| Dec 31 2020 | US$1m | US$287k | -US$12m |
Tazminat ve Piyasa: Lisa 'nin toplam tazminatı ($USD 1.46M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 652.98K ).
Tazminat ve Kazançlar: Lisa 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Lisa Ricciardi (66 yo)
Ms. Lisa R. Ricciardi serves as Chief Executive Officer and President at Cognition Therapeutics, Inc. since March 2020 and as Director since March 2019. She serves as an Independent Non-Executive Director...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 6.5yrs | US$1.46m | 0.52% $ 487.8k | |
| Chief Financial Officer | 3.3yrs | US$866.79k | 0.65% $ 608.3k | |
| Chief Medical Officer | 7.4yrs | US$927.89k | 0.27% $ 253.7k | |
| VP & Head of CMC | 3.2yrs | Veri yok | Veri yok | |
| Head of Quality | 2.7yrs | Veri yok | Veri yok | |
| Corporate Controller | 3.7yrs | Veri yok | Veri yok |
Deneyimli Yönetim: CGTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 7.5yrs | US$1.46m | 0.52% $ 487.8k | |
| Independent Director | 4.8yrs | US$68.52k | 0.062% $ 57.5k | |
| Independent Chairman of the Board | 6.2yrs | US$95.02k | 0.051% $ 47.7k | |
| Independent Director | 10yrs | US$61.02k | 0.091% $ 85.0k | |
| Member of Medical Advisory Board | 4.7yrs | Veri yok | Veri yok | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 5.9yrs | US$64.52k | 0.051% $ 47.7k | |
| Independent Director | 11.2yrs | US$59.52k | 0.059% $ 55.3k | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific & Biomarker Advisory Board | 7.8yrs | Veri yok | Veri yok | |
| Member of Medical Advisor Board | no data | Veri yok | Veri yok | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok |
Deneyimli Yönetim Kurulu: CGTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/14 23:41 |
| Gün Sonu Hisse Fiyatı | 2026/09/14 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Cognition Therapeutics, Inc. 6 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| null null | B. Riley Securities, Inc. |
| William Wood | B. Riley Securities, Inc. |